Feb 23 (Reuters) - Merus Labs International Inc MSL.TO :
* Announces inaugural deal with Sanofi (PA:SASY)
* To acquire the rights to Surgestone, Provames, Speciafoldine, and Tredemine
in France
* Says Merus acquired the product rights for a one-time payment of EUR22.5
million
* Says net revenue for the products in 2016 is expected to be approximately
EUR6.3 million
* At current exchange rates, the products are expected to generate
approximately $5.6 million in annual EBITDA
* Revised guidance for adjusted EBITDA during fiscal year ending September 30,
2016 to be $47 million to $50 million
* Says acquisition is expected to be funded with one third debt and two thirds
equity
Source text for Eikon
Further company coverage MSL.TO